Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1991 Jul;64(1):47–53. doi: 10.1038/bjc.1991.237

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.

D A Wolf 1, P Schulz 1, F Fittler 1
PMCID: PMC1977337  PMID: 1713053

Abstract

Experiments have been designed to investigate hormonal effects on the human prostatic carcinoma cell line LNCaP in the presence of complete foetal calf serum. At physiological concentrations (3.3 x 10(-9)M), several derivatives of 17 alpha-methyl-testosterone led to a significant reduction of cell proliferation, inhibition of colony formation in soft agar, change of morphology, induction of a prostate specific mRNA and down-regulation of c-myc RNA. Two different antiandrogens, hydroxyflutamide and cyproterone acetate, were capable of reversing the effects exerted by the synthetic androgens on growth properties. The proliferation rate of control cells devoid of androgen receptor was not inhibited by synthetic androgens. Our results indicate that the cellular androgen response mechanism of LNCaP cells is intact and that synthetic androgens elicit androgen receptor mediated suppression of the transformed phenotype. Rare cases of remission of prostatic cancer on androgen treatment have been reported. LNCaP cells may be a model of an uncommon class of prostatic cancer which responds favourably to androgen treatment.

Full text

PDF
47

Images in this article

50Figure 2
on p.50
50Figure 3
on p.50
51Figure 5
on p.51

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auffray C., Rougeon F. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur J Biochem. 1980 Jun;107(2):303–314. doi: 10.1111/j.1432-1033.1980.tb06030.x. [DOI] [PubMed] [Google Scholar]
  2. BRENDLER H., CHASE W. E., SCOTT W. W. Prostatic cancer; further investigation of hormonal relationships. Arch Surg. 1950 Sep;61(3):433–440. [PubMed] [Google Scholar]
  3. Berns E. M., de Boer W., Mulder E. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate. 1986;9(3):247–259. doi: 10.1002/pros.2990090305. [DOI] [PubMed] [Google Scholar]
  4. Bonne C., Raynaud J. P. Assay of androgen binding sites by exchange with methyltrienolone (R 1881). Steroids. 1976 Apr;27(4):497–507. doi: 10.1016/0039-128x(76)90084-2. [DOI] [PubMed] [Google Scholar]
  5. Challis J. R., Kim C. K., Naftolin F., Judd H. L., Yen S. S., Benirschke K. The concentrations of androgens, oestrogens, progesterone and luteinizing hormone in the serum of foetal calves throughout the course of gestations. J Endocrinol. 1974 Jan;60(1):107–115. doi: 10.1677/joe.0.0600107. [DOI] [PubMed] [Google Scholar]
  6. Corwin S. H., Malament M., Small M., Strauss H. D. Experiences with F-32 in advanced carcinoma of the prostate. J Urol. 1970 Nov;104(5):745–748. doi: 10.1016/s0022-5347(17)61826-3. [DOI] [PubMed] [Google Scholar]
  7. Eick D., Piechaczyk M., Henglein B., Blanchard J. M., Traub B., Kofler E., Wiest S., Lenoir G. M., Bornkamm G. W. Aberrant c-myc RNAs of Burkitt's lymphoma cells have longer half-lives. EMBO J. 1985 Dec 30;4(13B):3717–3725. doi: 10.1002/j.1460-2075.1985.tb04140.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Freedman V. H., Shin S. I. Cellular tumorigenicity in nude mice: correlation with cell growth in semi-solid medium. Cell. 1974 Dec;3(4):355–359. doi: 10.1016/0092-8674(74)90050-6. [DOI] [PubMed] [Google Scholar]
  9. Hasenson M., Hartley-Asp B., Kihlfors C., Lundin A., Gustafsson J. A., Pousette A. Effect of hormones on growth and ATP content of a human prostatic carcinoma cell line, LNCaP-r. Prostate. 1985;7(2):183–194. doi: 10.1002/pros.2990070208. [DOI] [PubMed] [Google Scholar]
  10. Holt J. T., Redner R. L., Nienhuis A. W. An oligomer complementary to c-myc mRNA inhibits proliferation of HL-60 promyelocytic cells and induces differentiation. Mol Cell Biol. 1988 Feb;8(2):963–973. doi: 10.1128/mcb.8.2.963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Horoszewicz J. S., Leong S. S., Chu T. M., Wajsman Z. L., Friedman M., Papsidero L., Kim U., Chai L. S., Kakati S., Arya S. K. The LNCaP cell line--a new model for studies on human prostatic carcinoma. Prog Clin Biol Res. 1980;37:115–132. [PubMed] [Google Scholar]
  12. Horoszewicz J. S., Leong S. S., Kawinski E., Karr J. P., Rosenthal H., Chu T. M., Mirand E. A., Murphy G. P. LNCaP model of human prostatic carcinoma. Cancer Res. 1983 Apr;43(4):1809–1818. [PubMed] [Google Scholar]
  13. Kaighn M. E., Narayan K. S., Ohnuki Y., Lechner J. F., Jones L. W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol. 1979 Jul;17(1):16–23. [PubMed] [Google Scholar]
  14. Klein G. The approaching era of the tumor suppressor genes. Science. 1987 Dec 11;238(4833):1539–1545. doi: 10.1126/science.3317834. [DOI] [PubMed] [Google Scholar]
  15. Klobeck H. G., Combriato G., Schulz P., Arbusow V., Fittler F. Genomic sequence of human prostate specific antigen (PSA). Nucleic Acids Res. 1989 May 25;17(10):3981–3981. doi: 10.1093/nar/17.10.3981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Lippman S. M., Kessler J. F., Meyskens F. L., Jr Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep. 1987 Apr;71(4):391–405. [PubMed] [Google Scholar]
  17. Michelson A. M., Markham A. F., Orkin S. H. Isolation and DNA sequence of a full-length cDNA clone for human X chromosome-encoded phosphoglycerate kinase. Proc Natl Acad Sci U S A. 1983 Jan;80(2):472–476. doi: 10.1073/pnas.80.2.472. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Prout G. R., Jr, Brewer W. R. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer. 1967 Nov;20(11):1871–1878. doi: 10.1002/1097-0142(196711)20:11<1871::aid-cncr2820201112>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  19. Raynor R. H., Hazra T. A., Moncure C. W., Mohanakumar T. Characterization of a monoclonal antibody, KR-P8, that detects a new prostate-specific marker. J Natl Cancer Inst. 1984 Sep;73(3):617–625. [PubMed] [Google Scholar]
  20. Reiss M., Gamba-Vitalo C., Sartorelli A. C. Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep. 1986 Jan;70(1):201–218. [PubMed] [Google Scholar]
  21. Robinson M. R., Thomas B. S. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J. 1971 Nov 13;4(5784):391–394. doi: 10.1136/bmj.4.5784.391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sager R. Tumor suppressor genes: the puzzle and the promise. Science. 1989 Dec 15;246(4936):1406–1412. doi: 10.1126/science.2574499. [DOI] [PubMed] [Google Scholar]
  23. Schulz P., Bauer H. W., Brade W. P., Keller A., Fittler F. Evaluation of the cytotoxic activity of diethylstilbestrol and its mono- and diphosphate towards prostatic carcinoma cells. Cancer Res. 1988 May 15;48(10):2867–2870. [PubMed] [Google Scholar]
  24. Schulz P., Bauer H. W., Fittler F. Steroid hormone regulation of prostatic acid phosphatase expression in cultured human prostatic carcinoma cells. Biol Chem Hoppe Seyler. 1985 Nov;366(11):1033–1039. doi: 10.1515/bchm3.1985.366.2.1033. [DOI] [PubMed] [Google Scholar]
  25. Schulz P., Stucka R., Feldmann H., Combriato G., Klobeck H. G., Fittler F. Sequence of a cDNA clone encompassing the complete mature human prostate specific antigen (PSA) and an unspliced leader sequence. Nucleic Acids Res. 1988 Jul 11;16(13):6226–6226. doi: 10.1093/nar/16.13.6226. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Schuurmans A. L., Bolt J., Mulder E. Androgen receptor-mediated growth and epidermal growth factor receptor induction in the human prostate cell line LNCaP. Urol Int. 1989;44(2):71–76. doi: 10.1159/000281473. [DOI] [PubMed] [Google Scholar]
  27. Schuurmans A. L., Bolt J., Mulder E. Androgens and transforming growth factor beta modulate the growth response to epidermal growth factor in human prostatic tumor cells (LNCaP). Mol Cell Endocrinol. 1988 Nov;60(1):101–104. doi: 10.1016/0303-7207(88)90124-4. [DOI] [PubMed] [Google Scholar]
  28. Schuurmans A. L., Bolt J., Mulder E. Androgens stimulate both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate. 1988;12(1):55–63. doi: 10.1002/pros.2990120108. [DOI] [PubMed] [Google Scholar]
  29. Schuurmans A. L., Bolt J., Voorhorst M. M., Blankenstein R. A., Mulder E. Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer. 1988 Dec 15;42(6):917–922. doi: 10.1002/ijc.2910420622. [DOI] [PubMed] [Google Scholar]
  30. Sonnenschein C., Olea N., Pasanen M. E., Soto A. M. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989 Jul 1;49(13):3474–3481. [PubMed] [Google Scholar]
  31. Stone K. R., Mickey D. D., Wunderli H., Mickey G. H., Paulson D. F. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer. 1978 Mar 15;21(3):274–281. doi: 10.1002/ijc.2910210305. [DOI] [PubMed] [Google Scholar]
  32. Veldscholte J., Ris-Stalpers C., Kuiper G. G., Jenster G., Berrevoets C., Claassen E., van Rooij H. C., Trapman J., Brinkmann A. O., Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 1990 Dec 14;173(2):534–540. doi: 10.1016/s0006-291x(05)80067-1. [DOI] [PubMed] [Google Scholar]
  33. Veldscholte J., Voorhorst-Ogink M. M., Bolt-de Vries J., van Rooij H. C., Trapman J., Mulder E. Unusual specificity of the androgen receptor in the human prostate tumor cell line LNCaP: high affinity for progestagenic and estrogenic steroids. Biochim Biophys Acta. 1990 Apr 9;1052(1):187–194. doi: 10.1016/0167-4889(90)90075-o. [DOI] [PubMed] [Google Scholar]
  34. Wakeling A. E., Furr B. J., Glen A. T., Hughes L. R. Receptor binding and biological activity of steroidal and nonsteroidal antiandrogens. J Steroid Biochem. 1981 Dec;15:355–359. doi: 10.1016/0022-4731(81)90297-1. [DOI] [PubMed] [Google Scholar]
  35. Wilding G., Chen M., Gelmann E. P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate. 1989;14(2):103–115. doi: 10.1002/pros.2990140204. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES